Literature DB >> 22669491

[Oral factor Xa inhibitors or warfarin for stroke prophylaxis. ROCKET AF and ARISTOTLE studies].

C Hammerstingl1, G Nickenig, S Nitschmann.   

Abstract

Entities:  

Year:  2012        PMID： 22669491     DOI： 10.1007/s00108-012-3106-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  7 in total

Review 1.  The new oral anticoagulants.

Authors:  David Garcia; Edward Libby; Mark A Crowther
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

2.  [Warfarin or dabigatran in patients with atrial fibrillation. RE-LY study (Randomized Evaluation of Long-term anticoagulation therapY)].

Authors:  T Meinertz; S Nitschmann
Journal:  Internist (Berl)       Date:  2011-04       Impact factor: 0.743

3.  Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.

Authors:  Amitava Banerjee; Deirdre A Lane; Christian Torp-Pedersen; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2011-12-21       Impact factor: 5.249

4.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

5.  A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.

Authors:  Harry R Buller; Anthonie W A Lensing; Martin H Prins; Giancarlo Agnelli; Alexander Cohen; Alexander S Gallus; Frank Misselwitz; Gary Raskob; Sebastian Schellong; Annelise Segers
Journal:  Blood       Date:  2008-07-11       Impact factor: 22.113

6.  Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.

Authors:  H Buller; D Deitchman; M Prins; A Segers
Journal:  J Thromb Haemost       Date:  2008-06-06       Impact factor: 5.824

7.  Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation.

Authors:  Elaine M Hylek; James D'Antonio; Carmella Evans-Molina; Carol Shea; Lori E Henault; Susan Regan
Journal:  Stroke       Date:  2006-03-09       Impact factor: 7.914
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.